Legend Biotech Soars with Strong Q2 2024 Results
Company Announcements

Legend Biotech Soars with Strong Q2 2024 Results

Legend Biotech (LEGN) has released an update.

Legend Biotech has reported robust second quarter results for 2024 with notable approvals for its CARVYKTI® treatment in multiple myeloma, showing strong sales and positive survival outcomes in clinical studies. The company’s financial health appears solid with a cash reserve of $1.3 billion, expected to sustain operations into 2026 when they predict achieving operating profit. These achievements, alongside the expansion of manufacturing capabilities, mark significant strides in Legend Biotech’s commitment to advancing cell therapy treatments.

For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyLegend Biotech initiated with a Buy at Redburn Atlantic
TheFlyLegend Biotech to open cell therapy R&D facility in Philadelphia
TipRanks Auto-Generated NewsdeskLegend Biotech’s CARVYKTI® Revolutionizes Multiple Myeloma Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App